JPWO2020056085A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020056085A5 JPWO2020056085A5 JP2021539337A JP2021539337A JPWO2020056085A5 JP WO2020056085 A5 JPWO2020056085 A5 JP WO2020056085A5 JP 2021539337 A JP2021539337 A JP 2021539337A JP 2021539337 A JP2021539337 A JP 2021539337A JP WO2020056085 A5 JPWO2020056085 A5 JP WO2020056085A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- spd
- cancer
- variant
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 34
- 102220289021 rs1555570093 Human genes 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 238000006467 substitution reaction Methods 0.000 claims 11
- 102220383933 c.199A>G Human genes 0.000 claims 9
- 102200006350 rs777354267 Human genes 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 102220543869 Protocadherin-10_S42G_mutation Human genes 0.000 claims 5
- 208000036142 Viral infection Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102220103991 rs764149793 Human genes 0.000 claims 3
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 208000021145 human papilloma virus infection Diseases 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731488P | 2018-09-14 | 2018-09-14 | |
| US62/731,488 | 2018-09-14 | ||
| US201962888320P | 2019-08-16 | 2019-08-16 | |
| US62/888,320 | 2019-08-16 | ||
| PCT/US2019/050742 WO2020056085A1 (en) | 2018-09-14 | 2019-09-12 | Spd-1 variant - fc fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535761A JP2021535761A (ja) | 2021-12-23 |
| JP2021535761A5 JP2021535761A5 (https=) | 2022-09-07 |
| JPWO2020056085A5 true JPWO2020056085A5 (https=) | 2022-09-07 |
Family
ID=68211179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539337A Pending JP2021535761A (ja) | 2018-09-14 | 2019-09-12 | ｓＰＤ−１バリアント−Ｆｃ融合タンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11498955B2 (https=) |
| EP (1) | EP3850003A1 (https=) |
| JP (1) | JP2021535761A (https=) |
| KR (1) | KR20210058902A (https=) |
| CN (1) | CN112969710A (https=) |
| AU (1) | AU2019338416A1 (https=) |
| CA (1) | CA3109983A1 (https=) |
| NZ (1) | NZ774126A (https=) |
| SG (1) | SG11202101904UA (https=) |
| TW (2) | TWI815964B (https=) |
| WO (1) | WO2020056085A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016164428A1 (en) * | 2015-04-06 | 2016-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway |
| EP3991741A1 (en) * | 2020-11-02 | 2022-05-04 | Klinikum rechts der Isar der Technischen Universität München | An immune checkpoint-modulating vsv-ndv hybrid virus for oncolytic virus immonotherapy of cancer |
| EP4243852A4 (en) * | 2020-11-13 | 2024-12-11 | Ludwig Institute for Cancer Research Ltd | PD-1 DECOY VARIANTS FOR IMMUNOTHERAPY |
| WO2022137186A1 (en) | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
| EP4274852A4 (en) * | 2021-01-11 | 2025-02-26 | Eutilex Co., Ltd. | BISPECIFIC EPITOP-BINDING PROTEIN WITH ANTI-4-1BB ANTIBODY AND PD-1 PROTEIN OR FRAGMENTS THEREOF AND USE THEREOF |
| EP4288080A1 (en) * | 2021-02-04 | 2023-12-13 | Helsingin Yliopisto | A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto |
| US20240141014A1 (en) * | 2021-03-03 | 2024-05-02 | Shattuck Labs, Inc. | Mutant pd-1 extracellular domains |
| WO2022238962A1 (en) | 2021-05-12 | 2022-11-17 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies |
| US20250115657A1 (en) * | 2021-05-28 | 2025-04-10 | Akso Biopharmaceutical, Inc. | Bispecific FC Fusion Proteins with sPD-1 and IL-15 |
| WO2023048518A1 (ko) * | 2021-09-24 | 2023-03-30 | 바이오엔시스템스 주식회사 | Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2693504A1 (en) * | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
| CN103261217B (zh) * | 2010-11-11 | 2017-04-26 | 港大科桥有限公司 | 可溶性 pd‑1变体、融合构建体及其用途 |
| US20150368316A1 (en) | 2013-02-07 | 2015-12-24 | Albert Einstein College Of Medicine Of Yeshiva University | A selective high-affinity immune stimulatory reagent and uses thereof |
| US9546206B2 (en) * | 2014-08-08 | 2017-01-17 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity PD-1 agents and methods of use |
| WO2016023001A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| WO2016164428A1 (en) | 2015-04-06 | 2016-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway |
| EP3303383A1 (en) * | 2015-06-05 | 2018-04-11 | iBio, Inc. | Endostatin fragments and variants for use in treating fibrosis |
| PL3368572T3 (pl) * | 2015-10-02 | 2022-09-12 | Symphogen A/S | Przeciwciała anty-PD-1 oraz kompozycje |
| WO2017123548A1 (en) | 2016-01-14 | 2017-07-20 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment |
| WO2018104473A1 (en) * | 2016-12-07 | 2018-06-14 | Oslo Universitetssykehus Hf | Compositions and methods for cell therapy |
| US12065476B2 (en) * | 2018-06-15 | 2024-08-20 | Alpine Immune Sciences, Inc. | PD-1 variant immunomodulatory proteins and uses thereof |
-
2019
- 2019-09-12 NZ NZ774126A patent/NZ774126A/en not_active IP Right Cessation
- 2019-09-12 SG SG11202101904UA patent/SG11202101904UA/en unknown
- 2019-09-12 CA CA3109983A patent/CA3109983A1/en active Pending
- 2019-09-12 US US16/569,105 patent/US11498955B2/en active Active
- 2019-09-12 WO PCT/US2019/050742 patent/WO2020056085A1/en not_active Ceased
- 2019-09-12 EP EP19786693.2A patent/EP3850003A1/en not_active Withdrawn
- 2019-09-12 CN CN201980060042.5A patent/CN112969710A/zh active Pending
- 2019-09-12 TW TW108133070A patent/TWI815964B/zh active
- 2019-09-12 KR KR1020217010801A patent/KR20210058902A/ko not_active Ceased
- 2019-09-12 AU AU2019338416A patent/AU2019338416A1/en not_active Abandoned
- 2019-09-12 JP JP2021539337A patent/JP2021535761A/ja active Pending
- 2019-09-12 TW TW112132395A patent/TW202348622A/zh unknown
-
2022
- 2022-10-10 US US17/962,983 patent/US20230131056A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021535761A5 (https=) | ||
| JP2025063029A5 (https=) | ||
| JPWO2020056085A5 (https=) | ||
| JP2005253469A5 (https=) | ||
| JP2012152218A5 (https=) | ||
| JP2024007554A5 (https=) | ||
| JP2005245460A5 (https=) | ||
| CA2225378A1 (en) | Cytokine that induces apoptosis | |
| JP2013027391A5 (https=) | ||
| JP2022062113A5 (https=) | ||
| IL309260A (en) | Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding | |
| JP2018531622A5 (https=) | ||
| JP7402864B2 (ja) | ポリユビキチンリンカーに結合された線形多機能性マルチマー生体分子及びその用途 | |
| CN105073977B (zh) | 重组酵母转化体和用其制备免疫球蛋白Fc片段的方法 | |
| HRP20250701T1 (hr) | Himerni protein papiloma virusa l1 | |
| Wang et al. | Expression, purification, and immunogenic characterization of Epstein–Barr virus recombinant EBNA1 protein in Pichia pastoris | |
| US7052867B2 (en) | Expression and secretion vector for human interferon alpha and process for producing human interferon alpha by employing same | |
| CN103333255A (zh) | 一种长效hiv‐1膜融合抑制剂 | |
| RU2021110064A (ru) | ГИБРИДНЫЕ БЕЛКИ ВАРИАНТА sPD-1—FC | |
| CN117801123B (zh) | 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法 | |
| CN102617734B (zh) | 抗FGF-2抗体Dab-2及其应用 | |
| US20110287484A1 (en) | Expression vector containing the major envelope protein p9 of cystovirus phi6 as a fusion partner, and process for producing a membrane protein using the same | |
| JP2009520480A5 (https=) | ||
| CA3226040A1 (en) | Optimized multabody constructs, compositions, and methods | |
| JPWO2020154540A5 (https=) |